Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I/II, 3-Arm, Open Label, Single Centre Study to Investigate the Safety and Effect of Oral GABA Therapy on Beta-Cell Regeneration in Type 1-diabetes Patients

Next Previous
Search
Trial Profile

A Phase I/II, 3-Arm, Open Label, Single Centre Study to Investigate the Safety and Effect of Oral GABA Therapy on Beta-Cell Regeneration in Type 1-diabetes Patients

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 17 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Alprazolam (Primary) ; Gamma amino butyric acid (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms ReGenerate-1

    • Most Recent Events

    • 10 May 2023 Results published in the Diamyd Medical AB Media Release
    • 20 Apr 2023 According to a Diamyd Medical AB media release, topline results are expected in the first half of May 2023; The topline results will include data on endogenous insulin producing capacity measured as stimulated C-peptide and hormonal response to hypoglycemia. Additional results including blood sugar control measured as HbA1c and data from continuos glucose monitoring are expected during the second half of May.
    • 27 Mar 2023 According to a Diamyd Medical AB media release, topline results are expected to be announced in April.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top